Abstract 15096: Demographics, Characteristics and Comparative Survival of Malignant Cardiac Tumors: Analysis From the Surveillance, Epidemiology and End-Results Registry
Introduction: We sought to describe the demographics, histopathology, and survival of patients with primary malignant cardiac neoplasms (PMCNs)
Methods: We searched the SEER 18-registry for PMCNs diagnosed from 1973-2011. We analyzed demographics, histopathology and survival comparing cardiac to non-cardiac involvement.
Results: Of 7,384,580 cancers in SEER, there were 625 PMCNs with incidence of 0.42 cases per 1,000,000 persons. Most patients were white (78.2%), male (54.1%), with mean age of 52 years. PMCNs were sarcomas (57.1%), lymphomas (24.0%), mesotheliomas (7.0%) and germ cell tumors or trophoblastic tumors (1.0%) and only 13% of the patients had a previous history of malignancy. Survival data were available for 575 patients at a mean follow-up of 20.3 months, at the end of which 468 (81.4%) patients had died. Mean survival was 27.2 months (95% CI: 23.8-30.6) with 1-, 3- and 5- year survival of 47%, 22%, and 17% (Figure 1). Cardiac sarcomas were associated with worst survival with 1-, 3-, 5- year survival at 47%, 16%, and 11% compared with lymphoma survival at 59%, 41%, and 34%, respectively (log rank test p<0.001). Cardiac lymphomas comprised 0.032% of all lymphomas and compared with systemic disease, patients with cardiac involvement had worse survival (65.0 vs 47.4 months, p<0.001). Of all sarcomas, 0.3% involved the heart, and compared to extra-cardiac disease patients with cardiac sarcomas were younger (52.8 vs 46.1 years, p<0.001), more often female (40.8% vs 47.1%, p<0.05), had less history of malignancy (12.7% vs 7.6%, p<0.005), more often operated (26.2 vs 60.4, p<0.001), and had worse survival (64.7 vs 21.4, p<0.001).
Conclusions: PMCNs are extremely rare but associated with dismal survival. Of all PMCN, sarcomas, lymphomas and mesotheliomas are the most common and compared to non-cardiac disease, heart involvement confers worse prognosis.
Author Disclosures: S. Al-Kindi: None. S.J. Park: None. G.H. Oliveira: None.
- © 2014 by American Heart Association, Inc.